Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Motoyuki Otsuka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2869-2881; OpenAlex author ID A5059311581, A5113249834. Sources: OpenAlex.

Their work

Papers
22 (first author 8, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
42
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 3 papers · 2025: 7 papers · 2026: 2 papers

Papers 22

  1. Association between Serum Human Satellite II RNA and miR-21-5p Levels and Time to Pancreatic Cancer Diagnosis in a Prospective Population-based Study. Co-author DOI 10.1097/mpa.0000000000002723↗
  2. Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1111/cas.70533↗
  3. WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway. Co-author DOI 10.1007/s00535-024-02192-x↗
  4. A case of pancreatic ductal adenocarcinoma growing within the pancreatic duct mimicking an intraductal tubulopapillary neoplasm. Last author DOI 10.1007/s12328-025-02098-y↗
  5. Current status of endoscopic ultrasound-guided antitumor treatment for pancreatic cancer. Last author DOI 10.1111/den.14815↗
  6. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Co-author DOI 10.1186/s12935-025-03894-9↗
  7. Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers17203287↗
  8. Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Last author DOI 10.7759/cureus.79001↗
  9. Correction: Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Last author DOI 10.7759/cureus.c365↗
  10. CA19-9-Positive Extracellular Vesicle Is a Risk Factor for Cancer-Associated Thrombosis in Pancreatic Cancer. First author DOI 10.1016/j.gastha.2024.02.005↗
  11. Satellite double-stranded RNA induces mesenchymal transition in pancreatic cancer by regulating alternative splicing. Co-author DOI 10.1016/j.jbc.2024.105742↗
  12. Association of screening tool scores with overall survival in older patients with unresectable gastrointestinal or biliary pancreatic cancer: A retrospective s… Last author DOI 10.1016/j.jgo.2024.101714↗
  13. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. Co-author DOI 10.1016/j.isci.2023.106021↗
  14. Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding. Last author DOI 10.1016/j.pan.2023.10.018↗
  15. Lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia via specific integrins. First author DOI 10.1002/ctm2.1089↗
  16. Smaller extracellular vesicles are released from pancreatic cancer cells by the alteration of the lipid composition under low glucose conditions. First author DOI 10.1016/j.bbrc.2022.11.040↗
  17. Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer. First author DOI 10.3389/fcell.2022.1023332↗
  18. Aberrant expression of a novel circular RNA in pancreatic cancer. First author DOI 10.1038/s10038-020-00826-5↗
  19. The biological role of metabolic reprogramming in pancreatic cancer. First author DOI 10.1002/mco2.37↗
  20. Satellite RNA Increases DNA Damage and Accelerates Tumor Formation in Mouse Models of Pancreatic Cancer. First author DOI 10.1158/1541-7786.mcr-18-0139↗
  21. Quantitation of circulating satellite RNAs in pancreatic cancer patients. First author DOI 10.1172/jci.insight.86646↗
  22. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Co-author DOI 10.1093/carcin/bgu136↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takahiro Seimiya · 11 shared papers, 2018–2026 · strength 2.04
  2. Takahiro Kishikawa · 10 shared papers, 2016–2026 · strength 1.71
  3. Kazuyuki Matsumoto · 7 shared papers, 2023–2025 · strength 1.68
  4. Mitsuhiro Fujishiro · 7 shared papers, 2022–2026 · strength 1.55
  5. Shigeru Horiguchi · 7 shared papers, 2023–2026 · strength 1.52
  6. Hironari Kato · 6 shared papers, 2023–2025 · strength 1.36
  7. Chikako Shibata · 7 shared papers, 2021–2026 · strength 1.33
  8. Yuki Fujii · 5 shared papers, 2023–2026 · strength 1.05
  9. Koichiro Tsutsumi · 4 shared papers, 2023–2026 · strength 0.97
  10. Kosei Takagi · 4 shared papers, 2025–2026 · strength 0.90
  11. Takuma Iwata · 5 shared papers, 2020–2025 · strength 0.82
  12. Kazunaga Ishigaki · 4 shared papers, 2022–2024 · strength 0.76
  13. Kazuhiko Koike · 7 shared papers, 2014–2024 · strength 0.76
  14. Ryosuke Sato · 3 shared papers, 2025 · strength 0.74
  15. Genso Notoya · 3 shared papers, 2024–2026 · strength 0.67
  16. Kazuya Yasui · 3 shared papers, 2025–2026 · strength 0.66
  17. Tatsunori Suzuki · 4 shared papers, 2018–2024 · strength 0.54
  18. Yasuo Nagai · 2 shared papers, 2025 · strength 0.44
  19. Takeyoshi Nishiyama · 2 shared papers, 2025 · strength 0.44
  20. Toshiyoshi Fujiwara · 2 shared papers, 2025 · strength 0.44
  21. Yousuke Nakai · 3 shared papers, 2014–2026 · strength 0.43
  22. Hideaki Ijichi · 3 shared papers, 2014–2025 · strength 0.41
  23. Daisuke Uchida · 2 shared papers, 2023–2026 · strength 0.36
  24. Tatsuya Kikuchi · 2 shared papers, 2023–2026 · strength 0.36
  25. Hiroyuki Terasawa · 2 shared papers, 2023–2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.